Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : YAP Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
NorthStar Medical Radioisotopes Partners with YAP Therapeutics for Radiopharma
Details : The collaboration aims to develop and produce radiopharmaceuticals aimed at treating cancer and other chronic diseases.
Product Name : Undisclosed
Product Type : Radiolabelled Compounds
Upfront Cash : Undisclosed
January 08, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : YAP Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : CLR 121225
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Cellectar
Deal Size : Undisclosed
Deal Type : Agreement
NorthStar Supplies Actinium-225 to Cellectar Biosciences for Therapeutic Use
Details : NorthStar will provide non-carrier added actinium-225 (n.c.a Ac-225) to Cellectar for use in CLR 121225, an actinium-labeled PLE, expected to enter a Phase 1 study in pancreatic cancer.
Product Name : CLR 121225
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 21, 2024
Lead Product(s) : CLR 121225
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Cellectar
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : 64-Cu SAR-bisPSMA
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Clarity Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
NorthStar Medical Enters Clinical Supply Agreement to Support Cu-67 SAR-bisPSMA Trials
Details : Under the agreement, NorthStar will be responsible for the production of 67Cu-SAR-bisPSMA drug product for Clarity’s Phase I/II and Phase III trials being developed in prostate cancer.
Product Name : 64-Cu SAR-bisPSMA
Product Type : Radiolabelled Compounds
Upfront Cash : Undisclosed
October 04, 2024
Lead Product(s) : 64-Cu SAR-bisPSMA
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Clarity Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : 225-Ac Rosopatamab Tetraxetan
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Convergent Therapeutics
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
NorthStar and Convergent Therapeutics Expand Collaboration on CONV01-alpha
Details : NorthStar will supply Convergent’s CONV01-alpha, a PSMA-targeted mAb, rosopatamab tetraxetan, linked to an alpha radiation emittier, Ac-225, for prostate cancer, with non-carrier added Ac-225 supply.
Product Name : CONV01-alpha
Product Type : Radiolabelled Compounds
Upfront Cash : Undisclosed
August 13, 2024
Lead Product(s) : 225-Ac Rosopatamab Tetraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Convergent Therapeutics
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Curadh
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, NorthStar will supply its high purity, n.c.a. Ac-225 to Curadh for use in its pioneering molecularly targeted radiation (MTR) programs for the treatment of common lethal tumors.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 29, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Curadh
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Bayer AG
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, NorthStar will provide Bayer with its environmentally preferred, non-carrier added Ac-225. NorthStar’s Ac-225 will be used by Bayer for several of its radiopharmaceutical programs, including Actinium-225 conjugated The...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 18, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Bayer AG
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Nucleus RadioPharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under terms of the agreement, NorthStar will supply its high purity, non-carrier added Ac-225 to Nucleus. Nucleus will use NorthStar’s Ac-225 for their customers’ Actinium-225 conjugated therapy programs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 27, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Nucleus RadioPharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inhibrx
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under this agreement with Inhibrx, NorthStar will support the development of a prespecified number of Inhibrx’s novel biologic products by providing the Ac-225 supply for the Actinium-225 Conjugated Therapy and access to its integrated radiopharmaceuti...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 01, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inhibrx
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Curie Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Curie Therapeutics will be provided with priority access to NorthStar’s high purity non-carrier added n.c.a Ac-225, which will be used to advance its multimodal pipeline of precision radiopharmaceuticals to address broad unmet needs in treatment of pat...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 06, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Curie Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : PNT2001,225-Ac
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Point Biopharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, NorthStar will provide POINT with its electron accelerator-produced Ac-225 and POINT will use NorthStar’s Ac-225 in studies of PNT2001, a next-generation Prostate-Specific Membrane Antigen for non-metastatic castrate-s...
Product Name : PNT2001
Product Type : Radiolabelled Compounds
Upfront Cash : Undisclosed
August 09, 2021
Lead Product(s) : PNT2001,225-Ac
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Point Biopharma
Deal Size : Undisclosed
Deal Type : Agreement